Placebo News and Research

RSS

Results of Phase IIb dose range finding of oglemilast in chronic obstructive pulmonary disease announced

Forest Laboratories, Inc. (NYSE: FRX) and Glenmark Pharmaceuticals S.A. (Switzerland), a wholly owned subsidiary of Glenmark Pharmaceuticals India (GPL) today announced top-line results from a Phase IIb dose range-finding study of oglemilast in patients with Chronic Obstructive Pulmonary Disease (COPD). Once-daily treatment with oglemilast did not show a statistically meaningful increase from baseline compared to placebo in the primary endpoint trough FEV1, a measure of pulmonary function that is decreased in patients with COPD. Oglemilast was well tolerated at all doses studied.

19 Aug 2009

Genentech announces Phase III study results for Avastin (bevacizumab) in combination with chemo in HER2-negative breast cancer

Genentech, Inc. today announced that a Phase III study (RIBBON 2) of Avastin (bevacizumab) in combination with chemotherapy increased the time women with metastatic HER2-negative breast cancer whose initial chemotherapy had stopped working lived without the disease worsening (progression-free survival or PFS), compared to chemotherapy alone.

18 Aug 2009

Aspirin improves survival after colorectal cancer diagnosis

Men and women who were diagnosed with colorectal cancer and began regular use of aspirin had a lower risk of overall and colorectal cancer death compared to patients not using aspirin, according to a study in the August 12 issue of JAMA.

18 Aug 2009

$Denosumab reduces fractures in postmenopausal women with osteoporosis$

Denosumab reduces fractures in postmenopausal women with osteoporosis

Fractures are a major cause of disability and health care costs among postmenopausal women. Now a study in the New England Journal of Medicine highlights an alternative therapy that prevents fractures in postmenopausal women with osteoporosis.

18 Aug 2009

Aeterna Zentaris announces results from trials of Cetrorelix in benign prostatic hyperplasia

AEterna Zentaris Inc. today reported Phase 3 results for its North American efficacy trial Z-033 and the safety trial Z-041 in benign prostatic hyperplasia (BPH), with its lead endocrinology compound for urology, cetrorelix pamoate. As announced on March 6, 2009, sanofi-aventis U.S. LLC entered into an agreement with AEterna Zentaris for the development, registration and marketing of cetrorelix in BPH for the U.S. market.

17 Aug 2009

Novel treatment reduces swollen livers

Viruses need living cells for replication and production of virus progeny. Thus far, antiviral therapy primarily targets viral factors but often induces therapy resistance. New improved therapies attempt to targets cellular factors that are essential for viral replication.

16 Aug 2009

Stanford researchers want FDA to require drug makers to state how new medications compare with similar, existing treatments

The labeling information that comes with prescription drugs tells you what’s known about the medication, but researchers from the Stanford University School of Medicine think it’s high time that the labeling tell you what isn’t known.

13 Aug 2009

Investigational, orally-inhaled therapy effective in treating migraines

A new study conducted at the Jefferson Headache Center at Thomas Jefferson University Hospital in Philadelphia, Pennsylvania shows an investigational, orally-inhaled therapy is effective in treating migraines.

12 Aug 2009

Aspirin improves survival after colorectal cancer diagnosis

11 Aug 2009

Vertebroplasty expert cites concerns about new study

A new study by Mayo Clinic researchers has given rise to more questions than answers about the effectiveness of vertebroplasty to treat osteoporotic spinal fractures.

11 Aug 2009

$Denosumab reduces fracture risk in men receiving androgen-deprivation therapy for prostate cancer$

Denosumab reduces fracture risk in men receiving androgen-deprivation therapy for prostate cancer

Twice-yearly treatment with denosumab, a new targeted therapy to stop bone loss, increased bone density and prevented spinal fractures in men receiving androgen-deprivation therapy for prostate cancer.

11 Aug 2009

Knopp Neurosciences to present phase 2 results of drug candidate in amyotrophic lateral sclerosis

Knopp Neurosciences Inc. said the results of a Phase 2 safety and tolerability study of KNS-760704 in amyotrophic lateral sclerosis (ALS) will be presented at the 20th International Symposium on ALS/MND in Berlin on December 9, 2009.

11 Aug 2009

Genzyme updates on Cerezyme supply plus 2009 financials

Genzyme Corporation (NASDAQ: GENZ) today provided an update on the impact of Cerezyme® (imiglucerase for injection) supply constraints on patient treatment regimens and on the company’s 2009 financial results. The company’s Fabrazyme® (agalsidase beta) supply constraint period, Fabrazyme dose conservation guidelines for patients, and Fabrazyme financial guidance are unchanged.

11 Aug 2009

Additional trial to be conducted for KYNAPID under FDA special protocol agreement

Cardiome Pharma Corp. (NASDAQ: CRME/TSX: COM) and its co-development partner Astellas Pharma US, Inc. ("Astellas") announced today that Astellas will undertake a single confirmatory additional Phase 3 clinical trial of KYNAPID(TM) (vernakalant hydrochloride) Injection for rapid conversion of atrial fibrillation to sinus rhythm. The trial, to be called ACT 5, is expected to begin enrolling patients by the end of 2009, with completion expected in the first half of 2011.

11 Aug 2009

Dendreon signs lease for new manufacturing facility in Union City, Ga

Dendreon Corporation (Nasdaq: DNDN) today announced it has signed a lease agreement with Majestic Realty Co. to build a 160,000 square-foot manufacturing facility in Union City, Ga., where it expects to manufacture PROVENGE(R) (sipuleucel-T) for patients with advanced prostate cancer. The state of Georgia will be hosting a ribbon-cutting ceremony on September 30.

10 Aug 2009

Array Biopharma reports Q4 and full year 2009 financials

Array reported revenue of $5.5 million for the fourth quarter of fiscal 2009, compared to revenue of $6.1 million for the same period in fiscal 2008. Array invested $21.3 million in proprietary research and development for the quarter to advance its seven wholly-owned drugs in clinical development and select discovery programs.

10 Aug 2009

Botanicals do not have an effect on hot flashes or on cognitive function in menopausal women

Two studies conducted by researchers at the University of Illinois at Chicago and Northwestern University have found that commonly used botanicals do not have an effect on hot flashes or on cognitive function in menopausal women.

6 Aug 2009

Percutaneous vertebroplasty exposed as ineffective

A world-first study involving Monash University and the Cabrini Research Institute in Melbourne has revealed the injection of bone cement into broken vertebrae is not an effective treatment for patients suffering painful osteoporotic fractures.

6 Aug 2009

Comparative effectiveness studies raise questions about vertebroplasty back pain treatment

New studies on treating back pain from a fractured spine could call more attention to the type of comparative effectiveness research health policy experts and President Barack Obama have embraced in their quest to increase quality of care while lowering costs.

6 Aug 2009

Experts on vertebroplasty contend recent vertebroplasty studies are misleading

Two studies released today in the New England Journal of Medicine claim to demonstrate that vertebroplasty, a procedure to treat some painful spine fractures, is not effective. This is incorrect, as both studies actually demonstrate a significant improvement in patients' pain and ability to function normally.

6 Aug 2009

Placebo News and Research

Results of Phase IIb dose range finding of oglemilast in chronic obstructive pulmonary disease announced

Genentech announces Phase III study results for Avastin (bevacizumab) in combination with chemo in HER2-negative breast cancer

Aspirin improves survival after colorectal cancer diagnosis

Denosumab reduces fractures in postmenopausal women with osteoporosis

Aeterna Zentaris announces results from trials of Cetrorelix in benign prostatic hyperplasia

Novel treatment reduces swollen livers

Stanford researchers want FDA to require drug makers to state how new medications compare with similar, existing treatments

Investigational, orally-inhaled therapy effective in treating migraines

Aspirin improves survival after colorectal cancer diagnosis

Vertebroplasty expert cites concerns about new study

Denosumab reduces fracture risk in men receiving androgen-deprivation therapy for prostate cancer

Knopp Neurosciences to present phase 2 results of drug candidate in amyotrophic lateral sclerosis

Genzyme updates on Cerezyme supply plus 2009 financials

Additional trial to be conducted for KYNAPID under FDA special protocol agreement

Dendreon signs lease for new manufacturing facility in Union City, Ga

Array Biopharma reports Q4 and full year 2009 financials

Botanicals do not have an effect on hot flashes or on cognitive function in menopausal women

Percutaneous vertebroplasty exposed as ineffective

Comparative effectiveness studies raise questions about vertebroplasty back pain treatment

Experts on vertebroplasty contend recent vertebroplasty studies are misleading

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News